Supplemental Figure Legend

Supplemental Figure. Flow Diagram of the Study Population

DM = diabetes mellitus; ITDM = insulin-treated diabetes mellitus; NITDM = non–insulin-treated diabetes mellitus

Supplemental Figure

Supplemental Table 1

Procedural Characteristics According to Sex and Diabetes Status

Women / P Value / Men / P Value / Overall P Value
No Diabetes
(n=1396) / Diabetes
(n=829) / No Diabetes
(n=4403) / Diabetes
(n=1954)
Vascular access site
Femoral / 95.4% (1332/1396) / 92.9% (770/829) / 0.01 / 95.9% (4224/4403) / 95.3% (1863/1954) / 0.28 / 0.002
Radial / 4.2% (59/1396) / 6.8% (56/829) / 0.009 / 3.9% (171/4403) / 4.6% (89/1954) / 0.21 / 0.003
Number of vessels treated / 1.2 ± 0.4 / 1.2 ± 0.4 / 0.92 / 1.2 ± 0.4 / 1.2 ± 0.5 / 0.16 / 0.007
Target vessel location
Left anterior descending artery / 48.1% (671/1396) / 47.2% (391/829) / 0.68 / 46.4% (2044/4403) / 43.1% (843/1954) / 0.02 / 0.02
Right coronary artery / 38.5% (537/1396) / 36.2% (300/829) / 0.28 / 36.9% (1624/4403) / 37.1% (725/1954) / 0.87 / 0.68
Left circumflex artery / 25.8% (360/1396) / 28.8% (239/829) / 0.12 / 31.0% (1367/4403) / 35.2% (688/1954) / 0.001 / <0.0001
Surgical graft / 2.2% (31/1396) / 4.5% (37/829) / 0.003 / 4.7% (208/4403) / 7.8% (153/1954) / <0.0001 / <0.0001
Number of lesion treated / 1.42 ± 0.70 (1396) / 1.48 ± 0.76 (829) / 0.05 / 1.52 ± 0.80 (4403) / 1.55 ± 0.82 (1954) / 0.16 / <0.0001
Number of stents implanted / 1.60 ± 0.91 (1396) / 1.66 ± 0.98 (829) / 0.14 / 1.75 ± 1.04 (4403) / 1.77 ± 1.04 (1954) / 0.33 / <0.0001
Total stent length, mm / 29.2 ± 19.6 (1396) / 30.8 ± 20.9 (829) / 0.08 / 33.3 ± 23.0 (4403) / 33.7 ± 23.1 (1954) / 0.46 / <0.0001
Any calcified lesion / 30.4% (425/1396) / 30.9% (256/829) / 0.83 / 29.7% (1308/4403) / 33.5% (655/1954) / 0.002 / 0.03
Any bifurcation lesion / 14.4% (201/1396) / 11.5% (95/829) / 0.05 / 17.1% (751/4403) / 14.3% (279/1954) / 0.005 / <0.0001
Any chronic total occlusion / 3.1% (43/1396) / 3.7% (31/829) / 0.40 / 5.4% (238/4403) / 4.8% (93/1954) / 0.28 / 0.002
Any thrombotic lesion / 14.7% (205/1396) / 8.4% (70/829) / <0.0001 / 17.6% (775/4403) / 11.9% (232/1954) / <0.0001 / <0.0001
Any in-stent restenosis / 8.2% (114/1396) / 10.9% (91/829) / 0.03 / 10.2% (448/4403) / 12.3% (241/1954) / 0.01 / 0.001
Any graft lesion / 2.2% (31/1396) / 4.5% (37/829) / 0.003 / 4.7% (208/4403) / 7.8% (153/1954) / <0.0001 / <0.0001

Values are % (n/N) or mean ± standard deviation (n).

Supplemental Table 2

Medication Use From Hospital Discharge Through 2 Years According to Sex and Diabetes Status

Women / P Value / Men / P Value / Overall P Value
No Diabetes
(n=1396) / Diabetes
(n=829) / No Diabetes
(n=4403) / Diabetes
(n=1954)
Aspirin
Discharge / 99.14% (1381/1393) / 99.16% (822/829) / 0.97 / 99.39% (4375/4402) / 98.87% (1930/1952) / 0.03 / 0.20
1 Year / 86.68% (1210/1396) / 83.35% (691/829) / 0.03 / 87.85% (3868/4403) / 87.36% (1707/1954) / 0.58 / 0.005
2 Years / 79.66% (1112/1396) / 77.56% (643/829) / 0.24 / 81.47% (3587/4403) / 80.14% (1566/1954) / 0.21 / 0.046
Clopidogrel
Discharge / 99.86% (1391/1393) / 99.40% (824/829) / 0.11 / 99.66% (4387/4402) / 99.64% (1945/1952) / 0.91 / 0.35
1 Year / 72.92% (1018/1396) / 73.46% (609/829) / 0.78 / 72.86% (3208/4403) / 73.95% (1445/1954) / 0.36 / 0.82
2 Years / 47.06% (657/1396) / 51.75% (429/829) / 0.03 / 45.49% (2003/4403) / 51.94% (1015/1954) / <0.0001 / <0.0001
Dual antiplatelet therapy
Discharge / 98.99% (1379/1393) / 98.55% (817/829) / 0.34 / 99.09% (4362/4402) / 98.57% (1924/1952) / 0.06 / 0.21
1 Year / 68.77% (960/1396) / 68.64% (569/829) / 0.94 / 69.84% (3075/4403) / 70.47% (1377/1954) / 0.61 / 0.65
2 Years / 42.26% (590/1396) / 46.68% (387/829) / 0.04 / 42.38% (1866/4403) / 47.70% (932/1954) / <0.0001 / 0.0002
Statin
Discharge / 91.2% (1273/1396) / 88.7% (735/829) / 0.05 / 93.0% (4096/4402) / 91.5% (1787/1954) / 0.03 / 0.0001
1 Year / 84.67% (1143/1350) / 83.00% (659/794) / 0.31 / 88.07% (3765/4275) / 85.09% (1609/1891) / 0.001 / <0.0001
2 Years / 81.47% (1051/1290) / 82.10% (610/743) / 0.72 / 85.58% (3496/4085) / 83.10% (1475/1775) / 0.01 / 0.0008
Proton pump inhibitor
Discharge / 29.7% (415/1396) / 27.3% (226/829) / 0.21 / 23.7% (1044/4402) / 24.4% (477/1954) / 0.55 / <0.0001
1 Year / 26.37% (356/1350) / 27.71% (220/794) / 0.50 / 20.24% (865/4273) / 23.97% (453/1890) / 0.001 / <0.0001
2 Years / 27.31% (352/1289) / 27.19% (202/743) / 0.95 / 19.73% (806/4085) / 23.44% (416/1775) / 0.001 / <0.0001
ACE inhibitors or ARB
Discharge / 79.4% (658/829) / 67.2% (938/1396) / <0.0001 / 70.0% (3080/4402) / 81.6% (1595/1954) / <0.0001 / <0.0001
1 Year / 67.19% (938/1396) / 79.37% (658/829) / 0.003 / 69.97% (3080/4402) / 81.63% (1595/1954) / <0.0001 / <0.0001
2 Years / 63.60% (877/1379) / 73.11% (598/818) / 0.02 / 67.97% (2966/4364) / 77.41% (1494/1930) / <0.0001 / <0.0001
Beta blockers
Discharge / 84.2% (1175/1396) / 82.4% (683/829) / 0.27 / 82.9% (3648/4402) / 83.9% (1639/1954) / 0.32 / 0.51
1 Year / 80.30% (1084/1350) / 76.95% (611/794) / 0.07 / 77.58% (3315/4273) / 79.47% (1502/1890) / 0.10 / 0.08
2 Years / 77.98% (1006/1290) / 76.85% (571/743) / 0.56 / 73.90% (3019/4085) / 76.73% (1362/1775) / 0.02 / 0.007
Calcium blockers
Discharge / 20.1% (280/1396) / 28.2% (234/829) / <0.0001 / 16.6% (731/4402) / 26.9% (525/1954) / <0.0001 / <0.0001
1 Year / 20.52% (277/1350) / 25.44% (202/794) / 0.008 / 16.73% (715/4273) / 25.24% (477/1890) / <0.0001 / <0.0001
2 Years / 23.33% (301/1290) / 26.65% (198/743) / 0.09 / 17.69% (723/4086) / 25.18% (447/1775) / <0.0001 / <0.0001
Diuretics
Discharge / 38.9% (543/1396) / 51.4% (426/829) / <0.0001 / 29.3% (1289/4402) / 44.9% (878/1954) / <0.0001 / <0.0001
1 Year / 35.78% (483/1350) / 49.24% (391/794) / <0.0001 / 26.16% (1118/4273) / 39.52% (747/1890) / <0.0001 / <0.0001
2 Years / 35.35% (456/1290) / 49.33% (366/742) / <0.0001 / 25.97% (1061/4086) / 39.10% (694/1775) / <0.0001 / <0.0001
Warfarin
Discharge / 5.2% (72/1396) / 5.7% (47/829) / 0.60 / 5.0% (219/4402) / 7.0% (136/1954) / 0.002 / 0.01
1 Year / 5.04% (68/1350) / 6.42% (51/794) / 0.18 / 4.70% (201/4273) / 8.36% (158/1890) / <0.0001 / <0.0001
2 Years / 5.35% (69/1290) / 8.21% (61/743) / 0.01 / 5.46% (223/4086) / 9.19% (163/1774) / <0.0001 / <0.0001

Values are % (n/N).

ACE =angiotensin-converting enzyme; ARB =angiotensinreceptor blocker.

Supplemental Table 3

Unadjusted 2-Year Outcomes According to Sex and Diabetes Status

Women / p Value* / Men / p Value* / Overall p Value*
No DM
(N=1,396) / NITDM
(N=458) / ITDM (N=371) / No DM
(N=4,403) / NITDM
(N=1,327) / ITDM (N=627)
Coronary thrombotic events / 3.5% (47) / 5.5% (24) / 11.5% (41) / <0.0001 / 4.2% (178) / 5.1% (65) / 9.1% (53) / <0.0001 / <0.0001
Stent thrombosis / 0.8% (11) / 0.8% (3) / 3.0% (11) / 0.009 / 0.9% (37) / 1.6% (20) / 1.7% (10) / 0.04 / 0.02
Myocardial infarction / 3.5% (47) / 5.1% (22) / 10.9% (39) / <0.0001 / 4.0% (171) / 4.8% (61) / 8.8% (51) / <0.0001 / <0.0001
Cardiac death, myocardial infarction, stent thrombosis / 5.0% (67) / 6.7% (29) / 14.3% (51) / <0.0001 / 5.2% (222) / 6.9% (89) / 12.5% (73) / <0.0001 / <0.0001
Cardiac death / 1.9% (25) / 2.0% (9) / 4.1% (14) / 0.06 / 1.4% (59) / 3.0% (37) / 5.1% (29) / <0.0001 / <0.0001
Death, myocardial infarction, target vessel revascularization / 13.5% (179) / 14.8% (65) / 26.5% (93) / <0.0001 / 13.3% (563) / 16.5% (213) / 26.9% (159) / <0.0001 / <0.0001
Target vessel revascularization / 8.7% (113) / 8.6% (37) / 16.7% (56) / <0.0001 / 8.5% (355) / 10.5% (133) / 16.7% (95) / <0.0001 / <0.0001
Clinically-relevant bleeding / 10.5% (141) / 8.4% (42) / 12.0% (41) / 0.65 / 8.1% (343) / 8.4% (107) / 11.1% (65) / 0.06 / 0.02
All-cause death / 3.7% (49) / 3.6% (16) / 6.2% (21) / 0.13 / 2.9% (121) / 4.4% (56) / 9.0% (53) / <0.001 / <0.0001

Results reported as number of events (Kaplan-Meier estimates), univariate hazard ratios, and 95% confidence intervals.

*Log-rank pvalue.

DM = diabetes mellitus; ITDM = insulin-treated diabetes mellitus; NITDM = non–insulin-treated diabetes mellitus.